Trial Profile
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Rituximab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms BLISS-BELIEVE
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 14 Nov 2022 Results of a meta-analysis by pooling individual patient MBC flow cytometry data from 1245 patients with SLE from from four randomised clinical trials (NCT00071487, NCT00410384, NCT01632241 and NCT01649765) and extensive B-cell subset phenotyping was performed prospectively by employing high-sensitivity flow cytometry (NCT03312907 and NCT03747159) presented at the ACR Convergence 2022.
- 04 Jun 2022 Results of a meta-analysis by pooling individual patient MBC flow cytometry data from 1245 patients with SLE from from four randomised clinical trials (NCT00071487, NCT00410384, NCT01632241 and NCT01649765) and extensive B-cell subset phenotyping was performed prospectively by employing high-sensitivity flow cytometry (NCT03312907 and NCT03747159) presented at the 23rd Annual Congress of the European League Against Rheumatism
- 04 Jun 2022 Results of an analysis assessed the pharmacodynamic effects of BEL and a single RTX cycle on immunologic biomarkers in adults with SLEpresented at the 23rd Annual Congress of the European League Against Rheumatism